Abstract OBJECTIVES: To examine the incidence and timing of new-onset left bundle branch block (LBBB) and new permanent pacemaker implantation (PPI) in patients undergoing transcatheter aortic valve implantation (TAVI) using the repositionable, self-expanding Portico TM TAVI system (St. Jude Medical, St Paul, MN, USA). Clinical impact and periprocedural factors associated with new PPI were also assessed.
INTRODUCTION
Conduction disturbances requiring new permanent pacemaker implantation (PPI) have been reported after transcatheter aortic valve implantation (TAVI). This may be caused by the proximity of the atrioventricular (AV) node and left bundle branch to the aortic valve [1] . Baseline and periprocedural factors associated with conduction disturbances requiring PPI have been extensively studied for several commercially available transcatheter aortic valves; with pre-existing right bundle branch block (RBBB), use of a self-expanding bioprosthesis, valve implantation depth and echocardiographic indices predictive of increased PPI risk [2] [3] [4] .
The clinical impact of new PPI following TAVI, however, remains controversial with conflicting data reporting either no effect on long-term patient survival [5] or increased risk of repeat hospitalization or mortality at 1 year [2] .
The Portico TM TAVI system (St. Jude Medical, St Paul, MN, USA) is an intra-annular, trileaflet bovine pericardial valve mounted within a self-expanding, nitinol stent frame. The low frame height and non-flared annular skirt with porcine pericardial cuff is designed to create an effective annular seal in the calcific native annulus to minimize the extension of the valve into the left ventricular outflow tract (LVOT) and provide a uniform distribution of radial force to the native annular tissue to reduce trauma to the conduction system (Fig. 1) . The ability of the Portico TAVI system to be repositioned and resheathed prior to full (80%) deployment may also reduce risk of conduction disturbances, as suboptimal annular positioning may be avoided.
The purpose of the current analysis was to examine the incidence of new-onset left bundle branch block (LBBB) and new PPI in high-risk patients who underwent TAVI using the selfexpanding Portico valve as part of the Portico TAVI system study. Clinical impact at 1 year and periprocedural factors associated with new PPI were also examined.
MATERIALS AND METHODS

Study population and design
The design and short-term outcomes of the Portico TAVI system study have been previously described [6] . Briefly, 222 patients with symptomatic severe aortic stenosis (AS) deemed by a local heart team to be high surgical risk were recruited from 12 sites in Europe (n = 11) and Australia (n = 1) as part of a prospective, single-arm, multicentre study (NCT01493284). The primary outcome of the Portico TAVI system study was all-cause mortality at 30 days with patient follow-up to 1 year. The study was conducted in compliance with the Declaration of Helsinki with ethics committee approvals obtained and all patients providing written informed consent. This study was sponsored by Abbott (formerly St. Jude Medical).
Patients received Portico valve implantation using the 18-or 19-Fr transfemoral delivery system between 7 December 2011 and 7 September 2015. Selection of 1 of the 4 Portico valve sizes (23, 25, 27 and 29 mm) was based on preprocedural imaging [multislice computed tomography (MSCT) or echocardiography] of the external native annulus diameter. Contrast fluoroscopy was performed to determine the correct positioning of the Portico valve in the aortic annulus. Periprocedural electrocardiography (ECG) and echocardiography were performed in all patients. After the procedure, patients returned for follow-up visits at 30 days and 1 year.
Twenty-four of the 222 patients had a pre-existing pacemaker, thus 198 patients were included in the current analysis. Incidence of new-onset conduction disturbances requiring PPI after TAVI and the clinical impact of new-onset LBBB and new PPI post-TAVI on mortality at 1 year were assessed. Predictors of new PPI based on ECG, echocardiography and MSCT imaging were also examined.
Electrocardiography
Twelve-lead ECG or EKG rhythm strip (procedure only) data were collected and analysed on-site at baseline, immediately prior to procedure, during valve implantation, post-procedure, at discharge and 30-day and 1-year follow-up. ECG data were assessed for heart arrhythmias and AV conduction disturbances. Ventricular pacing, defined as a pacing stimulus followed by a QRS complex, was assessed in patients with a new PPI at 30 days and 1 year.
Echocardiography
Transthoracic or transoesophageal echocardiographic evaluations were performed on-site at baseline, predischarge (24-48 h postimplantation) and at 30-day and 1-year follow-up. All echocardiograms were evaluated by an independent core laboratory.
Multislice computed tomography
Patients implanted with a 25, 27 and 29-mm Portico valve underwent preprocedural MSCT imaging. All contrast-enhanced computed tomography images were evaluated using analysis software (3mensio Medical Imaging BV, Bilthoven, Netherlands) by an independent core laboratory. Derived aortic annulus diameter, minimal and maximal diameter during systole, perimeter and area of the aortic annulus were assessed in the short-axis plane. Eccentricity index was calculated using the following formula: 1 -(minimum diameter/maximum diameter), with an eccentricity index >0.1 considered to be non-circular. Annulus ratio was calculated as minimum diameter:maximum diameter ratio of the aortic annulus.
Device oversizing was calculated as follows: [nominal valve perimeter (mm) -annulus perimeter (mm)]/annulus perimeter (mm) Â 100. Prostheses were categorized based on the derived aortic annular diameter as undersized, within sizing range or oversized, according to the manufacturer's recommendations. Severity of aortic valve and LVOT calcification was graded according to the adapted methods by Rosenhek et al. [7] . 
Measurement of valve implantation depth
Depth of valve implantation was determined from postdeployment aortic angiograms collected in an orthogonal view during the procedure. Mean implantation depth (mm) was defined as the length of the stent frame from the basal plane into the LVOT. Assessments were performed at the septal side of the non-coronary cusp (NCC) from the native aortic annulus to the inflow end of the stent frame. If necessary, offline reassessment of the post-deployment aortic angiogram was performed by the implanting physician to confirm implantation depth.
Pacemaker implantation and clinical end-points
Pacemaker implantation was conducted by a cardiac surgeon/ cardiologist according to the site's hospital guidelines. Pacemaker type was extracted from operative site reports and clinical notes. An independent Clinical Events Committee reviewed and adjudicated all indications for new PPI and cardiovascular-related deaths during 1-year follow-up.
Statistical analyses
Continuous variables were summarized using mean ± standard deviation. Categorical variables were summarized using frequencies and percentages. For comparisons between patients with versus without a new PPI at 1 year, a 2-sample t-test for normally distributed continuous variables or Wilcoxon rank-sum test for non-normally distributed continuous variables was used and the Fisher's exact test was used for categorical variables. Univariable logistic regression analyses were used to evaluate the association between baseline and procedural data and new PPI. Multivariable logistic regression models were performed using a stepwise selection process (entry: P > 0.15, stay: P < 0.050) to identify independent predictors of new PPI using all available data without imputation of missing predictor values. Variables were included in the multivariable models with a P-value <0.15 in the univariable analyses. The v 2 test was used to examine the association between new-onset LBBB and new PPI at 1 year. Kaplan-Meier estimates for freedom from all-cause and cardiovascular-related mortality at 1 year were compared between patients with versus without new PPI or new-onset LBBB at the time of discharge using a log-rank test. Statistical significance was set at P-value <0.050. All statistical analyses were performed using SAS TM Version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics and procedural details
Baseline demographics and clinical characteristics of the 198 patients included in the current analyses, stratified by the need for new PPI at 1 year are summarized in Supplementary Material, Table S1 . A total of 196 patients were successfully implanted with a Portico valve. Two patients underwent an attempted 25-mm Portico valve implant. One patient required the implantation of another commercially available aortic valve after becoming severely hypotensive and resistive to drug therapy, and in the 2nd patient, the procedure was abandoned because of difficulties in advancing the sheath.
Overall, patients were elderly (mean age 83.1 ± 4.7 years), predominately women (77.3%) and deemed to be high surgical risk based on assessment by the site's local heart team and confirmation by an independent subject selection committee. Patients received a similar proportion of Portico valve sizes: 23 mm (n = 44), 25 mm (n = 51), 27 mm (n = 54) and 29 mm (n = 49). Preexisting rhythm and/or conduction disturbances were present in 77 patients; the most common being atrial fibrillation (22.2%). Analysable 12-lead ECG data were available for 171 of the 193 eligible (alive and enrolled in the study) patients at hospital discharge, 161 of the 186 eligible patients at 30 days and 138 of the 142 eligible patients at 1 year.
A total of 33 patients implanted with a Portico valve required new PPI within 1 year (16.7%). With the exception of pre-existing RBBB, which was observed more frequently in patients with new PPI (12.1% vs 0.6% without new PPI; P = 0.003), baseline clinical characteristics were similar between the 2 patient groups (Supplementary Material, Table S1 ). Echocardiography identified several anatomical differences between the patient groups (Table 1) . Specifically, patients with new PPI had a larger aortic annulus diameter (P = 0.001), larger LVOT diameter (P < 0.001), larger LVOT area (P < 0.001), smaller ratio of LVOT diameter to annulus diameter (P = 0.001), smaller left ventricular 2D mass (P = 0.048) and smaller left ventricular ejection fraction (P = 0.02). Baseline MSCT imaging also reported a larger mean-derived aortic annulus diameter (P = 0.004), perimeter (P = 0.001) and area (P = 0.002) in patients with new PPI. No differences in annulus ratio, eccentricity index and aortic valve and outflow calcification were reported between the patient groups ( Table 1) .
Procedural characteristics are presented in Table 2 . Implantation of a 25-mm Portico valve was associated with a significantly lower rate of new PPI at 1 year (6.1%), compared to a 23-, 27-and 29-mm valve (27.3%, 33.3%, 33.3%, respectively; P = 0.02). In patients with available MSCT data, the valve was oversized by 10.09 ± 4.04% in patients with new PPI compared with 12.14 ±3.53% without new PPI (P = 0.016). However, no significant difference was observed in the proportion of patients with an oversized valve according to the manufacturer's sizing recommendations (oversized: 0% with new PPI vs 6.1% without new PPI; P = 0.37).
Stent protrusion into the LVOT was similar between the patient groups (P = 0.50). No difference was observed in the proportion of patients reporting stent protrusion into the LVOT > _5 mm with versus without new PPI (75.0% vs 74.1%; P = 1.00). No other intraprocedural factors including valve resheathing and postdilatation were observed to impact new PPI.
Indications and timing for new permanent pacemaker implantation
Of the 33 patients with new PPI at 1 year; 14 patients had a pacemaker implanted on the day of the index procedure, 15 patients at the time of discharge and 1 patient by 30 day follow-up (15.2%). An additional 3 patients required a new PPI between 30 days and 1 year (16.7%; Fig. 2 ). An acquired 3rd-degree AV block was the main indication for new PPI (23 of 33; 69.7%), followed by sinus bradycardia (n = 5), bradycardia (n = 2), other arrhythmias (n = 2) and asystole (n = 1). Patients were implanted with a dual-chamber (n = 19), single-chamber (n = 8), cardiac resynchronization therapy (n = 2) or unspecified (n = 4) pacemaker. In patients with new PPI, ECG analysis revealed ventricular pacing in 50% of patients at 30 days and 65.2% of patients at 1 year.
New-onset left bundle branch block following transcatheter aortic valve implantation
In the 187 patients without a pre-existing LBBB, 53 (28.3%) patients developed new-onset LBBB during 1-year follow-up (Fig. 2) . Overall, 23 patients developed new-onset LBBB during the procedure; in 39.1% (n = 9), this occurred immediately after valvuloplasty. Another 23 patients developed new-onset LBBB after the procedure until the time of discharge (within 7 days of procedure 
Independent predictors of new permanent pacemaker implantation
Univariable and multivariable logistic regression analyses are presented in Table 3 . Significant independent predictors of new PPI included pre-existing RBBB (P = 0.004) and aortic annulus diameter (mm) (P = 0.001).
Mortality
The Kaplan-Meier freedom from all-cause mortality at 1 year was comparable between patients with versus without new PPI at the time of discharge (92.7% vs 87.6%, P = 0.49; Fig. 3A) ; similar findings were observed for cardiovascular-related mortality at 1 year (96.6% vs 92.0%, P = 0.47; Fig. 3B ). New-onset LBBB did not predict new PPI at 1 year (P = 0.64). New-onset LBBB at the time of discharge was similarly not shown to be associated with increased mortality at 1 year (Supplementary Material, Fig. S1 ).
DISCUSSION
The current analysis of 198 symptomatic severe aortic stenosis patients without prior pacemaker can be summarized as follows: (i) new PPI rate after transfemoral implantation of the Portico valve was 15.2% at 30 days and 16.7% at 1 year; (ii) new-onset LBBB was common during the implant procedure and resolved in the majority of the patients at 30 days; (iii) no intraprocedural factors were shown to independently predict new PPI and (iv) freedom from all-cause and cardiovascular-related mortality at 1 year was similar between patients with versus without new PPI at discharge. The observed rate of new PPI at 1 year is comparatively lower than rates previously reported for the CoreValve TM selfexpanding valve [8, 9] and Lotus TM mechanical expanding valve [10] . Recent analyses of patients undergoing TAVI with the latest generation Sapien TM 3 balloon-expandable valve also report new PPI rates of 14.4-18.4% [11, 12] , which is consistent with that observed in the current study. The observed difference in pacemaker rates between the Portico valve and other prostheses may be explained partly by valve placement in the native annulus. The Portico valve is implanted intra-annularly compared to the CoreValve valve that is anchored in a subannular position. Intra-annular placement of the Portico valve coupled with a non-flared stent skirt design minimizes the extension of the stent frame into the LVOT reducing the likelihood of traumatic compression of the stent frame against tissue of the conduction system. The large stent cell design additionally minimizes the amount of metal contact with the conduction tissue. In the study, the majority of pacemakers were implanted within 7 days of the implant procedure (29 of 33) as a result of an acquired 3rd-degree AV block. Importantly, receiving a permanent pacemaker at the time of discharge was not shown to influence post-TAVI mortality, which is in agreement with a recent meta-analysis of 17 studies that found no association between periprocedural PPI and risk of all-cause or cardiovascular mortality at 1 year [13] .
Ventricular pacing was documented in approximately half of all new PPI patients at 30 days and two-thirds of patients at 1 year. The absence of ventricular pacing in >50% of patients with a pacemaker post-TAVI is not uncommon [2, 14] and may reflect prophylactic pacemaker implantation in some patients with satisfactory native conduction. In this study, no pacing guidelines were mandated; individual sites followed their own hospital procedures.
Incidence of new-onset LBBB in the study was 28.3% at 1 year, which is consistent with other studies [5, 15] . ECG tracings collected during key stages of the implant procedure identified balloon valvuloplasty as an important mediator of proceduralrelated new-onset LBBB, with 9 of the 23 cases reported occurring immediately post-valvuloplasty. New-onset LBBB was also prominent within 7 days of the index procedure (23 of 53 patients; 43.4%). Due to the properties of nitinol, self-expanding stent frames can continue to expand in the native annulus for several hours following the initial TAVI procedure leading to delayed injury to the left bundle branch. The majority of newonset LBBB events spontaneously resolved without treatment at 30 days, confirming the transient nature of LBBB following TAVI. New-onset LBBB did not predict the need for new PPI, and newonset LBBB at the time of discharge was not associated with a higher mortality rate at 1 year (Supplementary Material, Fig. S1 ).
As previously reported [2, 4] , pre-existing RBBB was a strong independent predictor for new PPI in the present study with 4 of 5 patients with a pre-existing RBBB requiring a new PPI. Preoperative echocardiography and MSCT identified several anatomical factors that were more prominent in patients requiring new PPI. Specifically, a larger aortic annulus and LVOT coupled with a smaller LVOT to aortic annulus diameter ratio and reduced LVEF was associated with new PPI. Significant discordance between the size of the LVOT and the native aortic annulus may increase mechanical tension and oedema in the intraventricular septum at the level of the prosthetic stent frame within the LVOT and lead to LBBB or high-grade AV block requiring PPI. In the present study, the only anatomical feature that was shown to be an independent predictor for new PPI was aortic annulus diameter.
Procedurally, the need for post-dilatation, postimplant balloon size and valve resheathing did not influence the need for new PPI. The lack of association with post-dilatation is consistent with other studies [9, 11] and possibly due to careful balloon sizing in relation to the size of the native annulus. No difference was observed in aortic valve or LVOT calcification among patients with versus without a new PPI at 1 year. This finding is consistent with a recent single-centre study of 104 patients implanted with the mechanically expanded Boston Lotus Valve [3] and may be explained by the small proportion of patients who reported severe valve (19.0%) and severe outflow (0.7%) calcification in the study. A significant difference in new PPI rate was observed between the different Portico prosthesis sizes. Specifically, patients implanted with a 25-mm valve reported an exceptionally low new PPI rate of 6.1% at 1 year. The reason for this phenomenon is unclear, as adherence to prosthesis sizing according to manufacturers' recommendations was high (86.9%) and not shown to influence the need for new PPI (P = 0.37). In patients with available MSCT data for whom it was possible to determine valve oversizing based on the nominal perimeter of the Portico valve, a modest, albeit significantly higher, percentage of oversizing was reported for patients without a new PPI. Caution is warranted in the interpretation of this finding as the Portico valve unlike other prostheses is designed to accommodate a certain degree of oversizing, and the mean percentage of oversizing reported for the 2 patient groups falls within the acceptable range of oversizing for each valve size.
In contrast with other studies [3, 11] , depth of stent frame into the LVOT was not a significant predictor of new PPI. Implantation depth in the current study was limited to a single measurement on the side of the NCC. Although implantation depth from the NCC is shown to be a strong predictor of 30-day pacing requirement [3] due to its proximity to the cardiac conduction system, the average depth of stent frame into the LVOT as measured from the LCC, NCC and right coronary cusp may provide a more accurate measure from which to predict new PPI. Some studies have looked at optimal implantation depth and impact on new PPI [9] . In the present study, a suboptimal implantation depth (defined as > _5 mm) was not shown to influence the need for new PPI. Further investigation is needed to understand the interplay between depth of valve implantation and conduction disturbances requiring new PPI following implantation of the Portico valve.
Limitations
This study has several limitations. MSCT-derived valve oversizing and aortic annulus parameters (perimeter, area and derived diameter) were not included in the multivariable logistic regression analysis due to only some patients undergoing MSCT imaging at baseline. The initial protocol did not mandate MSCT imaging in patients implanted with a 23-mm valve. The protocol was subsequently amended to require patients scheduled for implantation of a 25-, 27-or 29-mm valve to undergo preimplant MSCT imaging. Therefore, the multivariable analysis may not have identified all independent predictors for new PPI. In this study, comprehensive pacemaker interrogation by an electrophysiologist to assess patients underlying electrical activity and duration of time spent dependent on the pacemaker was not performed. Instead pacemaker dependency was determined from a ventricular paced rhythm (programmed using patientspecific parameters) detected at each follow-up visit. Data from the pivotal US IDE trial, which includes mandatory MSCT and ECG core laboratory analyses, will help confirm the findings from the current study. Finally, the absence of 24-h continuous ECG monitoring may have failed to identify all instances of periodic higher grade AV block after TAVR.
CONCLUSION
At 1 year, incidence of new-onset LBBB and new PPI was 28.3% and 16.7%, respectively, following the Portico valve implantation. In this study, independent predictors of new PPI were limited to pre-existing RBBB and large aortic annulus diameter. Importantly, no adverse effect of new-onset LBBB and new PPI post-TAVI on mortality risk was observed. Additional large-scale studies are required to better elucidate longer term outcomes and procedural factors that impact the risk for new PPI with the use of the Portico TAVI system.
